SAMRC Launches New Research Unit to Accelerate Preeclampsia Diagnosis and Maternal Health

In May 2026, the South African Medical Research Council (SAMRC) announced the establishment of a new Extramural Research Unit (EMU) dedicated to preeclampsia at Stellenbosch University’s Faculty of Medicine and Health Sciences. This initiative represents a significant advancement in addressing one of the leading causes of maternal and neonatal mortality globally.

Preeclampsia Research Expansion Creates New Avenues for Diagnostic Solutions

Cluver expressed gratitude, stating, "It is a tremendous honor to be selected as a South African Medical Research Council Extramural Research Unit. This award will support our continuous efforts to discover new therapeutics and diagnostics for preeclampsia, promote evidence-based medicine, and foster the development of the next generation of researchers."

The Unit builds upon over a decade of research at Stellenbosch University, where the Preeclampsia Research Unit is internationally recognized for its contributions. Its endeavors include the leading PROVE Biobank, cutting-edge clinical trials that test new treatments to prevent and manage preeclampsia, and collaborations with renowned organizations such as the World Health Organization and the Cochrane Library, which contribute to global evidence.

Preeclampsia remains a principal contributor to maternal and neonatal morbidity and mortality worldwide, with an estimated 46,000 to 70,000 maternal fatalities and approximately 500,000 fetal and neonatal deaths occurring annually. The burden of this condition is particularly pronounced in low- and middle-income countries, where the only definitive treatment currently available is delivery.

Market Outlook and Industry Impact

As per precedence research, the global preeclampsia diagnostics market size accounted for USD 1.29 billion in 2025 and is expected to increase from USD 1.33 billion in 2026 to approximately USD 1.70 billion by 2034, expanding at a CAGR of 3.10% from 2025 to 2034. The market is growing due to growing awareness of maternal health, technological advancements in point-of-care testing, and rising prenatal screening initiatives.

This research program brings together a diverse range of expertise, including scientists, clinicians, imaging specialists, and public health experts. This collaboration reflects a strong commitment to interdisciplinary innovation.

The primary goal of the program is to develop improved strategies for the prevention, diagnosis, and treatment of preeclampsia, aiming to decrease its significant global impact, particularly in low- and middle-income countries.

Leading organizations allocate substantial resources to remain at the forefront of innovation, continuously enhancing the accuracy and efficiency of diagnostic tools for preeclampsia. Strategic collaborations and partnerships are crucial as companies build alliances with research institutions, healthcare providers, and other industry stakeholders.